Pharmaceuticals: Restrictions in Use and Availability: Combination Products: Trancylopramine and trifluoperazine

Pharmaceuticals: Restrictions in Use and Availability
(2001; 40 pages)

Table of Contents

	Introduction
		Scope and presentation
		Criteria for the inclusion of pharmaceutical products in the UN Consolidated List
	Monocomponent products
		Alatrofloxacin mesilate
		Aldesleukin
		Amineptine
		Amfepramone hydrochloride
		Aristolochia
		Astemizole
		Bromfenac
		Buprenorphine
		Buspirone hydrochloride
		Camphor
		Chlormezanone
		Cisapride
		Dantron
		Dequalinium
		Dexfenfluramine hydrochloride
		Diphenoxylate
		Doxycycline hydrochloride (capsules)
		Dronabinol
		Ebrotidine
		Epoetin alfa and epoetin beta
		Erythrityl tetranitrate
		Fenfluramine
		Flunitrazepam
		Furazolidone
		Gentamicin (topical preparations)
		Grepafloxacin hydrochloride
		Ginkgo biloba
		Ketamine hydrochloride
		Ketorolac
		Lamivudine
		Levamisole hydrochloride
		Lexipafant
		Loxoprofen sodium
		Medifoxamine
		Mepacrine
		Metamizole sodium
		Methylrosanilinium chloride
		Metoclopramide (paediatric)
		Mibefradil
		Misoprostol
		Nandrolone
		Oxeladin citrate
		Pexiganan
		Phenolphthalein
		Phentermine
		Phentolamine mesilate
		Phenylbutazone
		Piperazine
		Promethazine
		Proxibarbal
		Pyrithione zinc
		Pumactant
		Rituximab
		Sertindole
		Sibutramine
		Sulfaguanidine
		Terfenadine
		Tilbroquinol
		Tolcapone
		Tramadol
		Troglitazone
		Trovafloxacin mesilate
		Zopiclone
	Combination Products
		Combination barbiturate product
		Barbiturates in asthma preparations
		Clopamide, reserpine and dihydroergocristine mesilate
		Kaolin and pectin
		Loratadine and pseudoephedrine
		Metamizole sodium, fenpiverinium bromide and pitofenone hydrochloride
		Pseudoephedrine and phenylpropanolamine
		Streptomycin and penicillin
		Trancylopramine and trifluoperazine
	Group Products
		Anorectic agents
		Ionic contrast media
		Mercuric derivatives (topical)
		Pyrethroids

Trancylopramine and trifluoperazine

Product name: Trancylopramine and trifluoperazine

Country	Effective Date	Description of action taken Grounds for decision
United Kingdom	1999	The licence for the antidepressant, trancylopramine and trifluorperazine has not been renewed by the Committee on Safety of Medicines because of concerns over drug interactions and the risk of severe hypertensive crises. As a result the company have withdrawn the product from the market. (Reference: Current Problems in Pharmacovigilance Vol. 25, June 1999.)